LSL Pharma Group Inc. LSL.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -476.03% | -1,801.39% | -124.46% | -202.72% | 25.43% |
| Total Depreciation and Amortization | 52.00% | 81.23% | 56.44% | 69.56% | 102.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 63.03% | 20.95% | 59.92% | 249.46% | -7.09% |
| Change in Net Operating Assets | 151.73% | -66.82% | 1,031.86% | -936.82% | 161.02% |
| Cash from Operations | -24.04% | -666.69% | 115.70% | -4,929.94% | 1,474.42% |
| Capital Expenditure | 7.77% | 31.20% | -133.31% | 29.71% | 53.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -124.13% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -68.57% | -136.75% | 31.78% | -324.10% | -165.43% |
| Cash from Investing | -34.47% | -38.00% | -100.77% | -11.18% | 69.91% |
| Total Debt Issued | -68.99% | 202.15% | 37.37% | 395.28% | 1,184.93% |
| Total Debt Repaid | 7.90% | -13.52% | -2.54% | -814.51% | 42.55% |
| Issuance of Common Stock | -- | -- | -- | 136.98% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -9.75% | -48.76% | -96.92% | -149.88% | 24.97% |
| Cash from Financing | -90.80% | 380.93% | 87.95% | 6.99% | 15.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -95.83% | 292.52% | -24.71% | -3,482.64% | 1,371.95% |